Hormonal and hemodynamic effects of aliskiren and valsartan and their combination in sodium-replete normotensive individuals

被引:50
作者
Azizi, Michel
Menard, Joel
Bissery, Alvine
Guyene, Than-Tam
Bura-Riviere, Alessandra
机构
[1] Hop Europeen Georges Pompidou, Ctr Invest Clin, Assistance Publ Hop Paris, F-75908 Paris 15, France
[2] Univ Paris 05, Fac Med, Paris, France
[3] INSERM, CIC 9201, Paris, France
来源
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2007年 / 2卷 / 05期
关键词
D O I
10.2215/CJN.00360107
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background and Objectives: An AT, receptor antagonist induces a counterregulatory renin release whose intensity and duration reflect the magnitude of the renin-angiotensin blockade. We investigated whether a renin inhibitor may neutralize this counterregulation and amplify the effects of AT, receptor antagonists. Design, Setting, Participants, & Measurements: In 12 normotensive male individuals who were on a high-sodium diet, a double-blind, placebo-controlled, randomized, crossover design was used to study the hormonal and BP effects of single oral administrations of 300 mg of the renin inhibitor aliskiren, 320 mg of valsartan, and a combination of these two drugs, each at half dosage (150 mg of aliskiren and 160 mg of valsartan). Results: Valsartan (320 mg) increased plasma renin activity and angiotensin I and angiotensin II levels, but 300 mg of aliskiren decreased them for 48 It. Aliskiren (300 mg) stimulated immunoreactive renin release more strongly than 320 mg of valsartan, decreased urinary aldosterone excretion for longer than 320 mg of valsartan, and had a similar BP-lowering effect as 320 mg of valsartan. In combination, 150 mg of aliskiren neutralized the valsartan (160 mg)-induced increase in plasma angiotensins for 48 h. The renin and aldosterone effects of the combination of 150 mg of aliskiren and 160 mg of valsartan were similar to those of 300 mg of aliskiren and greater than those of 320 mg of valsartan. When plasma drug concentrations were taken into account, the combination of 150 mg of aliskiren and 160 mg of valsartan had a synergistic effect on renin release. The BP-lowering effect of 150 mg of aliskiren and 160 mg of valsartan was similar to that of 300 mg of aliskiren and 320 mg of valsartan at peak but was more prolonged. Conclusion: The stronger and longer lasting effects on plasma active renin and urinary aldosterone of aliskiren, alone or in combination, demonstrate a more effective blockade of the renin-angiotensin system than that obtained with 320 mg of valsartan alone.
引用
收藏
页码:947 / 955
页数:9
相关论文
共 36 条
[1]   Body mass index and angiotensin-dependent control of the renal circulation in healthy humans [J].
Ahmed, SB ;
Fisher, NDL ;
Stevanovic, R ;
Hollenberg, NK .
HYPERTENSION, 2005, 46 (06) :1316-1320
[2]   Adjusting for multiple testing when reporting research results: The Bonferroni vs Holm methods [J].
Aickin, M ;
Gensler, H .
AMERICAN JOURNAL OF PUBLIC HEALTH, 1996, 86 (05) :726-728
[3]   Sodium glomerulopathy: Tubuloglomerular feedback and renal injury in African Americans [J].
Aviv, A ;
Hollenberg, NK ;
Weder, AB .
KIDNEY INTERNATIONAL, 2004, 65 (02) :361-368
[4]   Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption [J].
Azizi, M ;
Ménard, J ;
Bissery, A ;
Guyenne, TT ;
Bura-Rivière, A ;
Vaidyanathan, S ;
Camisasca, RP .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2004, 15 (12) :3126-3133
[5]   Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists [J].
Azizi, M ;
Ménard, J .
CIRCULATION, 2004, 109 (21) :2492-2499
[6]   Integrating drug pharmacokinetics for phenotyping individual renin response to angiotensin II blockade in humans [J].
Azizi, M ;
Bissery, A ;
Lamarre-Cliche, M ;
Ménard, J .
HYPERTENSION, 2004, 43 (04) :785-790
[7]   ADDITIVE EFFECTS OF COMBINED ANGIOTENSIN-CONVERTING ENZYME-INHIBITION AND ANGIOTENSIN-II ANTAGONISM ON BLOOD-PRESSURE AND RENIN RELEASE IN SODIUM-DEPLETED NORMOTENSIVES [J].
AZIZI, M ;
CHATELLIER, G ;
GUYENE, TT ;
MURIETAGEOFFROY, D ;
MENARD, J .
CIRCULATION, 1995, 92 (04) :825-834
[8]   Should we employ combination ACEI and ARB therapy in primary hypertension? [J].
Carey, Robert M. .
CURRENT HYPERTENSION REPORTS, 2006, 8 (02) :101-102
[9]  
Denny SD, 2006, AM J MED, V119, P327, DOI [10.1016/j.amjmed.2005.08.027, 10.1016/j.amjmed.2005.10.042]
[10]  
DERKX FHM, 1992, J BIOL CHEM, V267, P22837